Clinical Laserthermia Systems AB (CLS-B) Fair Value & Analysis
Healthcare · SE · Market cap 106M SEK (≈ $11.0M) · ISIN SE0002756130
What is Clinical Laserthermia Systems AB really worth?
Below-average quality, and trading another 83% above our fair value of kr 1.04.
As of Sep 5, 2026, the fair value of Clinical Laserthermia Systems AB is kr 1.04 per share against a price of kr 1.90, so the fair value sits 45% below the price. A model estimate blended from multiple valuation models, recalculated regularly.
Risks
Fair value as of: Sep 5, 2026
From 1 valuation models · updated today
Share price +3.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (kr 1.30). The favourable scenario is already priced in.
- Weak quality (23/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- A fairly wide model range (kr 0.6800 to kr 1.30) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 5, 2026.
How to read this chart
60‑month range kr 1.80 – kr 327.90 · fair‑value band kr 0.6800 – kr 1.30 · the kr 1.90 price screens above the kr 1.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 5, 2026.
Analysis
Clinical Laserthermia Systems AB (CLS-B) currently trades at kr 1.90, while our model-based Fair Value estimate is kr 1.04, implying the stock looks roughly 82.7% overvalued today. The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector. How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.
Trailing-twelve-month revenue stands at 14.3M SEK. Revenue declined 71.6% year over year. It earns a return on equity of −53.2%. The balance sheet holds a net cash position of 21.5M SEK. Fundamentals as of Sep 5, 2026
Our scenario range runs from kr 0.6800 (bear case) to kr 1.30 (bull case); at kr 1.90, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −45%, CLS-B screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 1 models by family
Notify me when CLS-B reaches fair value
Put CLS-B on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 30 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue.
Full company description
Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The company also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers that provides multiple options to control treatment. In addition, it offers various gauge laser applicators and introducers, as well as provides temperature and treatment monitoring devices. The company has a strategic partnership with ClearPoint Neuro Inc. for the development of ClearPoint Prism, a Neuro Laser Therapy System. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Clinical Laserthermia Systems AB reported revenue of 17.5M SEK in FY2025 versus 2.2M SEK in FY2021, a compound +67.1%/yr. Reported net income was −41.6M SEK in FY2025.
CLS-B screens 83% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 352 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Sep 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $112.47 | $74.79 | −34% |
| Stryker Corporation SYK | $322.12 | $186.28 | −42% |
| Medtronic plc MDT | $89.97 | $65.57 | −27% |
| Boston Scientific Corporation BSX | $46.84 | $30.73 | −34% |
| Edwards Lifesciences Corporation EW | $89.78 | $41.02 | −54% |
| Siemens Healthineers AG SHL | €39.52 | €33.87 | −14% |
| DexCom, Inc DXCM | $90.82 | $38.95 | −57% |
| GE HealthCare Technologies Inc GEHC | $74.82 | $64.13 | −14% |
| Koninklijke Philips N.V PHIA | €23.69 | €14.36 | −39% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥150.63 | ¥147.63 | −2% |
Compare Clinical Laserthermia Systems AB with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Clinical Laserthermia Systems AB (CLS-B) overvalued or undervalued?
What is the fair value of CLS-B?
What is the quality score of CLS-B?
What is the revenue of Clinical Laserthermia Systems AB (CLS-B)?
Watch Clinical Laserthermia Systems AB in the live analysis
One click puts Clinical Laserthermia Systems AB on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.